Date/Time
Date(s) - 19 Aug 2025
8:00 AM - 9:00 AM
Join us for an enlightening conversation with Kiran Avancha, co-founder of priZm Therapeutics, a late-stage clinical biotech company based in Chandler, Arizona. Kiran will share his journey building a company focused on developing breakthrough therapies for ultra-rare pediatric diseases—including their lead program, SRW101, a novel synthetic T3 molecule for treating AHDS (Allan-Herndon-Dudley Syndrome).
From early research to late-stage development, Kiran’s story offers a behind-the-scenes look at navigating the challenges of rare disease innovation and building a mission-driven biotech that puts children’s health at the forefront.
Register Now
Kiran Avancha, Ph.D., R.Ph, CCRP
Dr. Avancha is Chief Innovation Officer at HonorHealth where he is responsible for generating deal flow, investment thesis and innovation strategies. His work includes building strategic collaborations, partnerships, and running due diligence, and investment process across new and emerging modalities in therapeutics, devices, digital health, and healthcare solutions as well as establishing and leading HonorHealth Innovations (H2I) as a needs-based enterprise wide business unit in health-system.
He is also a Co-Founder at PriZm Therapeutics, a late-stage clinical biotech company with a focus on rare pediatric orphan diseases.